NDA Resubmission Addresses Issues Related to Vial Compatibility –
– If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly
https://finance.yahoo.com/news/gilead-resubmits-drug-application-u-203000139.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.